Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15065944 | 0.79 | MAPT (0.56) | MAPTL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL410179 | 0.78 | NPC1 (0.54) | MAPTL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15088138 | 0.78 | NPC1 (0.50) | MAPTL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30296621 | 0.75 | ALDH1A1 (0.38) | MAPTL3MBTL1SMN1; SMN2LMNATDP1 | |
| SCHEMBL30296220 | 0.75 | NPC1 (0.35) | MAPTL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30666961 | 0.75 | MAPT (0.56) | MAPTL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7311893 | 0.75 | NPC1 (0.56) | MAPTL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17224562 | 0.75 | MAPT (0.56) | MAPTL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23835195 | 0.74 | NPC1 (0.46) | MAPTL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3923636 | 0.73 | MAPT (0.66) | MAPTL3MBTL1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | MAPT 4580/4885L3MBTL1 4129/4885NPC1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.